Silverback Therapeutics

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible.

Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Silverback Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $22.1B in funding across 100 round(s). With a team of 11-50 employees, Silverback Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Silverback Therapeutics, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.